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Abstract 
 
Globally, death due to cancers is likely to rise to over 20 million by 2030, which has 
created an urgent need for novel approaches to anticancer therapies such as the development 
of host defence peptides. Cn-AMP2 (TESYFVFSVGM), an anionic host defence peptide from 
green coconut water of the plant, Cocos nucifera, and showed anti-proliferative activity against 
the 1321N1 and U87MG human glioma cell lines with IC50 values of 1.25 and 1.85 mM 
respectively. The membrane interactive form of the peptide was found to be an extended 
conformation, which primarily included β-type structures (levels > 45%) and random coil 
architecture (levels > 45%). Based on these and other data, it is suggested that the short anionic 
N-terminal sequence (TES) of Cn-AMP2 interacts with positively charged moieties in the 
cancer cell membrane. Concomitantly, the long hydrophobic C-terminal sequence 
(YFVFSVGM) of the peptide penetrates the membrane core region, thereby driving the 
translocation of Cn-AMP2 across the cancer cell membrane to attack intracellular targets and 
induce anti-proliferative mechanisms. This work is the first to demonstrate that AHDPs have 
activity against human glioblastoma, which potentially provides an untapped source of lead 
compounds for development as novel agents in the treatment of these and other cancers. 
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Introduction 
Globally, cancer is now one of the leading causes of death which claimed lives at an 
annual rate of over 12.7 million in 2008 and is predicted to rise to over 20 million by 2030, [1], 
which has created an urgent need for novel approaches to anticancer therapies [2-4]. In 
response, there has been a move to develop anticancer strategies that are based on compounds 
from natural sources [5-8], including host defence peptides (HDPs) [9-11]. These peptides are 
multi-functional components of innate immune systems across the eukaryotic kingdom [12, 
13] that show a potent ability to kill a wide variety of cancer cells [9, 11] and microbes [12, 
14]. The vast majority of HDPs are cationic (CHDPs) [15, 16], which underpins their ability to 
discriminate against the membranes of healthy mammalian cells, which possess no overall 
charge, and target the membranes of microbial and cancer cell, which possess a net anionic 
charge [9, 11, 12, 14]. Numerous studies have shown that membrane interaction is fundamental 
to the antimicrobial and anticancer activity of CHDPs and that in both cases, these interactions 
involve generally similar mechanisms [17]. In some instances, these mechanisms involve the 
translocation of these peptides across the plasma membranes of target cells to attack 
intracellular targets such as bacterial DNA [18, 19] or cancer cell mitochondria [20, 21]. 
However, most usually, the antimicrobial and anticancer mechanisms used by CHDPs involve 
direct attack on the membranes of target cells themselves, which can lead to death of the host 
cell via a variety of membranolytic processes that involve lipid perturbation and 
permeabilisation of the bilayer. [9, 11, 12, 14]. A number of major models have been proposed 
to describe these processes such as the carpet mechanism and the toroidal pore model [17] with 
more recent examples, including; the tilted peptide mechanism [22] and amyloid-mediated 
mechanisms [23].  
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It is generally believed that the relatively non-specific nature of the processes involved 
in the antimicrobial and anticancer action of CHDPs renders it unlikely that resistance to this 
action can be acquired by microbes [12, 14] and cancer cells [9, 11].  In the fight against rising 
global levels of cancer [24] and microbial infections [25, 26], this gives CHDPs a major 
advantage over conventional antibiotics and anticancer compounds, which show declining 
efficacy largely due to the increasing occurrence of multi-drug resistance in both microbial 
[27] and cancer cells [28]. In response, the therapeutic potential of CHDPs has been intensively 
investigated with the result that a number of these peptides are either in late-stage clinical trials 
or medical use as antimicrobial agents [29, 30] whilst most recently, the neutraceutical protein, 
lactoferrin, was patented as an anticancer agent [31] and in clinical trials, was shown to reduce 
the risk of colon carcinogenesis [32]. It has been predicted that many more CHDPs will soon 
advance to the stage of clinical trials as anticancer agents in the light of recent research progress 
[20, 21]. Nonetheless, in addition to CHDPs, anionic HDPs (AHDPs) have been increasingly 
recognised as an integral and important part of the innate immune system and thereby as a 
potential source of antimicrobial agents with novel mechanisms of action [33, 34]. There have 
been very few studies on the anticancer  activity of AHDPs [35] and here, we have investigated 
the anticancer ability of Cn-AMP2 (TESYFVFSVGM), which is an AHDP from green coconut 
water with broad range antibacterial activity [36], against the human glioma cell lines, 1321N1 
and U87MG. 
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Materials and Methods 
Reagents  
Cn-AMP2 [36]  was supplied by Pepceuticals (UK), produced by solid phase synthesis and 
purified by HPLC to greater than 99%, which was confirmed by MALDI mass spectrometry. 
The peptide was stored as a stock solution of 3 mM in dimethylsulphoxide (DMSO; 2% v/v) 
at -20°C. All phospholipids were supplied by Avanti Polar Lipids (USA). SVGp12, a non-
cancerous foetal glial cell line, along with the human glioma cell lines 1321N1 (grade II) and 
U87MG (grade IV) were obtained from the European Collection of Cell Cultures, UK. 
Cisplatin was purchased from Sigma-Aldrich (UK). 
 
 
 
Growth conditions for cancer cell lines 
The SVGp12 cell line was maintained in Essential Minimum Eagle Medium (EMEM) 
supplemented with 2.5% (v/v) FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 1% (v/v) 
non-essential amino acids (NEAA) (Lonza, UK). The 1321N1 and U87MG cell lines were 
maintained in Dulbeccos’s Modified Eagle’s Medium (DMEM) supplemented with 2.5% (v/v) 
foetal bovine serum (FBS) and 2 mM L-glutamine (Lonza, UK). Each of these cell lines was 
maintained in a 37 ºC humidified incubator supplied with 5% CO2, all as previously described 
[37]. 
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The effect of Cn-AMP2 on cell lines  
The SVGp12 cell line was grown as described above, trypsinised and seeded in 96-well 
microtitre plates (Sarstedt, UK) such that wells contained a cell density of 4500 cells / 200 µl. 
in EMEM with an FBS concentration of 2.5% (v/v). The 1321N1 and U87MG cell lines were 
similarly cultured except that wells contained DMEM with an FBS concentration of 2.5% (v/v) 
and were seeded to give rise to cell densities of 4000 cells / 200 µl and 3500 cells / 200 µl 
respectively, all as previously described [37].  The following day when the cells were circa 
60% confluent, Cn-AMP2 (final concentration varying between 0.25 mM and 2.0 mM) was 
added to wells and the plates left to incubate for 72 h. After this period of incubation, the 
membrane integrity (a) and viability (b) of these peptide-treated cells was ascertained: 
(a) The membrane integrity of the SVGp12, 1321N1 and U87MG cells was examined 
either by recording images using an inverted microscope (Leica Microsystems, UK) or utilising 
the Trypan blue exclusion test (Sigma Aldrich, UK) according to manufacturer’s instructions. 
Essentially, 10 µl of Trypan Blue Dye was added to wells under investigation and the cells in 
these wells then observed under a microscope to identify Trypan blue staining, which is 
indicative of cell membrane lysis. As controls, these experiments were repeated in the absence 
of the peptide and, in all cases, experiments were performed in quadruplicate. 
(b) The viability of cell lines was determined using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, UK; MTS assay [38]) according to manufacturer’s 
instructions. Essentially, 20 µl of pre-warmed MTS reagent was added to wells under 
investigation and the plates incubated at 37 oC in a humidified incubator supplied with 5% CO2 
for 60 min. At the end of this time, the absorbance of each well was recorded at 490 nm using 
a Tecan GENios Pro® microplate reader and used to determine % cell viability. As controls, 
these experiments were repeated in the absence of the peptide and, in all cases, experiments 
were performed in quadruplicate. Non-linear regression analysis was used to yield the 
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concentration of Cn-AMP2 that inhibited 50% of cancer cell growth (IC50) when compared to 
untreated controls. 
 
 
Figure 1. The effect of Cn-AMP2 on the viability of cell lines 
 
 
 
 
 
Figure 1 shows the effect of Cn-AMP2 on the viability of cell lines when incubated as described 
above. Increasing concentrations of the peptide led to progressively larger reductions in the 
viability the human glioma cell lines, 1321N1 and U87MG, until at a Cn-AMP2 concentration 
2.0 mM, these reductions were circa 70% as compared to controls. In contrast, at the same 
peptide concentration, Cn-AMP2 induced reductions in the viability of the non-cancerous, 
human glial cell-line, SVGp12, of circa 25% as compared to controls. Cell viability was 
determined by the MTS assay as described above and each data entry was the mean of 4 repeats 
and the error bars represent ± the standard deviation. Regression analysis of these data entries 
yielded IC50 values for Cn-AMP2 that were 1.25 mM for the 1321N1 cell line and 1.85 mM 
for U87MG cell line. 
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Sequence analysis and molecular modelling of Cn-AMP2 
The primary structure of Cn-AMP2, TESYFVFSVGM, was obtained from [36] and the 
potential of the peptide to adopt membrane interactive α-helical structure determined by 
hydrophobic moment plot analysis. This methodology uses the mean hydrophobic moment, < 
µH >, to measure the structured partitioning of hydrophobic and hydrophilic amino acid 
residues in a regular repeat structure [39, 40]. Molecular dynamic (MD) simulations to model 
the interactions of Cn-AMP2 with a DMPC:DMPS (10:1) bilayer were undertaken. The peptide 
was assembled using the AMBER tools 1.5 program [41] and minimized using the 
GROMOS53a6 force field (2,3), which was equilibrated at room temperature in water. All 
simulations were performed with GROMACS software package [42, 43]. The force field for 
DMPS and DMPC was based on the GROMOS53a6 force fields with minor modification taken 
from the literature [44]. All structures were equilibrated at room temperature in water (NVT 
and NPT simulations) and bilayers contained 128 lipids in a box, which was 6.53 nm x 6.53 
nm x 10.0 nm parallel to the z- axis. The GROMOS96 force field step descendent method was 
utilised to minimise the structure and, employing a 400 ns equilibration run at 310 K, 
simulations were performed using the NPT ensemble. The Cn-AMP2 molecule was inserted 
into the box containing the solvated bilayer and an equilibration run was carried out for the 
system. The stability of association of the peptide with the surface of the DMPC:DMPS (10:1) 
bilayer was estimated by determining the energy required to induce Cn-AMP2 to occupy a 
location in the membrane interior, which was performed using the potential of mean force 
(PMF) facility available in Gromacs [45]. The potential energy of the system was extracted for 
slower pulling simulations with a pulling rate of 0.1 Å/ns for 40 ns and Cn-AMP2 was pulled 
in the direction parallel to the Z axis (5). 
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Figure 2. The effects of Cn-AMP2 on the morphology of cell lines         
1321N1                 (C)                                                                          (D) 
U87MG                  (A)                                                                         (B) 
SVGp12                  (E)                                                                          (F) 
Figure 2 shows cells of the human glioma cell lines, U87MG (Figure 2A) and 1321N1 (Figure 
2C), along with the non-cancerous glial cell line, SVGp12 (Figure 2E), that had been cultured 
in the presence of Cn-AMP2 at a peptide concentration of 2 mM. Also shown are cells of the 
same cell lines that had been similarly cultured but in the absence of Cn-AMP2 (Figures B, D 
and F). It can be clearly seen that samples treated with the peptide showed no evidence of cell-
death, as indicated by a round morphology; and no sign of cell lysis, as witnessed by membrane 
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fragmentation or the presence of cellular debris. All images are at a 10 X magnification and 
scale bars in the images represent 350 µM. All cell lines were cultured as described above.  
 
Table 1. Secondary structural contributions to Cn-AMP2 
Medium % α-helix % β-turns and sheet % Random coil 
PBS (pH 7.5) 8 46 46 
TFE (50% v/v) 4 47 49 
DMPC 7 46 47 
DMPS 3 49 47 
DMPC / DMPS 
(10:1) 
5 48 48 
 
 
 
The preparation of SUVs 
Small unilamellar vesicles (SUVs) were constructed with a mean diameter of 0.1 μM 
all as previously described [46]. Essentially, either pure lipids or lipid mixtures were dissolved 
in chloroform (5 mg ml-1), dried under N2 and further dried under vacuum overnight. The 
resulting lipid film was rehydrated using phosphate buffered saline [PBS; pH 7.5] containing 
NaCl (150 mM) and sonicated for an hour or until the solution was no longer turbid. To form 
SUVs, these solutions were then freeze-thawed (× 5) and extruded (× 11) using an Avanti polar 
lipid mini-extruder apparatus containing a 0.1 µm polycarbonate filter (Avanti, USA). 
 
CD structural analyses of Cn-AMP2 
Cn-AMP2 (0.1 mg ml-1) was dissolved in either phosphate buffered saline [PBS; pH 
7.5] or 50% (v/v) trifluorethanol (TFE). The peptide was also dissolved in suspensions of 
SUVs, of either DMPC, DMPS or DMPC / DMPS (10:1), all prepared as described above, to 
give a peptide to lipid molar ratio of 1:100.  All samples were analyzed at 20 °C on a J-815 
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spectropolarimeter (Jasco, UK) over a wavelength range of 260 to 180 nm, using a band width 
of 1 nm and a scan speed of 100 nm min-1. For all spectra produced, the baseline acquired in 
the absence of Cn-AMP2 was subtracted and levels of secondary structure in the peptide 
estimated using Dichroweb [47-49]. 
 
The membranolytic ability of Cn-AMP2 
Calcein release assay: SUVs were prepared from either DMPC, DMPS or DMPC / DMPS 
(10:1) all as described above except that lipid (7.5 mg) was dissolved in chloroform. After 
drying, the resulting lipid film was hydrated with 1 ml of HEPES (5 mM; pH 7.5) containing 
calcein (70 mM). SUVs with entrapped calcein were separated from free calcein by gel 
filtration using HEPES (5 mM; pH 7.5) as an elutant and a Sephadex G75 column (SIGMA), 
which was hydrated over-night with HEPES (20mM; pH 7.4) containing NaCl (150 mM) and 
EDTA (1.0 mM). The ability of Cn-AMP2 to lyse these SUVs was determined by assaying 
calcein release. Essentially, aliquots (20 µl) of solutions containing SUVs with entrapped 
calcein and Cn-AMP2 at final concentrations in the range 0 µM to 400 µM were incubated 
with 2 ml of HEPES (20 mM; pH 7.4) containing NaCl (150 mM) and EDTA (1.0 mM). The 
fluorescence intensity of released calcein was measured using a FP-6500 spectrofluorometer 
(JASCO, Tokyo Japan) with an excitation wavelength of 490 nm and an emission wavelength 
of 520 nm. The change in fluorescence observed for calcein release when SUVs were dissolved 
in Triton-X100 (20 µl) was taken to represent 100% lysis and used to determine the percentage 
lysis of these SUVs by Cn-AMP2.  
 
Haemolysis assay: The haemolytic activity of Cn-AMP2 was investigated using a standard 
assay [50, 51].  Essentially, fresh human red blood cells (3 ml) were washed 3 times with 
phosphate buffered saline (PBS, pH 7.4) by centrifugation for 5 minutes at 1200 × g until the 
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supernatant was clear.  Washed red blood cells were resuspended in PBS to a final volume of 
20 ml.  Peptide solutions (10 µl) were added to 190 µl suspension of washed red blood cells 
and were incubated for 1h at 37 °C.  The samples were then centrifuged at 12000 × g for 5 
minutes. The release of haemoglobin was monitored by diluting 100 µl of supernatant with 900 
µl PBS and measuring the absorbance at 576 nm. For negative and positive controls, PBS buffer 
and 0.1% Triton X-100 were used.   
 
Results and discussion 
There is an urgent need for new anticancer agents with novel mechanisms of action and 
it has been predicted that AHDPs may be an untapped source of such agents [33, 34]. Plants 
are known to be prolific producers of novel anticancer compounds [7, 52, 53] and the biggest 
single source of AHDPs with anticancer activity [35]. Accordingly, here, we have investigated 
the ability of Cn-AMP2, which is an AHDP found in green coconut water, derived from Cocos 
nucifera of the Arecaceae [36], to inactivate the human glioma cell lines, 1321N1 and U87M. 
It was found that increasing concentrations of Cn-AMP2, led to progressively larger reductions 
in the viability of cell lines until at a peptide concentration 2.0 mM, these reductions were circa 
70% (Figure 1). In contrast, across the same concentration range, the peptide induced 
reductions in the viability of the non-cancerous, glial cell-line, SVGp12, of circa 25% (Figure 
1). Regression analysis of these data yielded IC50 values for Cn-AMP2 that were 1.25 mM for 
the 1321N1 cell line and 1.85 mM for the U87MG cell line as compared to untreated controls. 
In combination, these results show that Cn-AMP2 has selective toxicity for cancer cells and 
comparable results were recently reported for the anticancer activity of Cr-ACP1, which is an 
AHDP that was recently isolated from Cycas revolute, a plant of the Cycadaceae family [54]. 
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Figure 3. CD structural analysis of Cn-AMP2 
 
 
 
Figure 3 shows CD spectra of Cn-AMP2 in aqueous solution (black), in TFE (dotted black), 
which is an α-helix promoting solvent, and in the presence of small unilamellar vesicles 
(SUVs), which were formed from a range of membrane lipids. These SUVs include those 
formed from: DMPC (grey) and DMPS (light grey) respectively, which are the major anionic 
and zwitterionic lipids in cancer cell membranes, and DMPC / DMPS (10:1) (dotted grey), 
which can be taken as representative of cancer cell membranes . Levels of secondary structure 
possessed by the peptide were determined from these spectra and in all cases examined, Cn-
AMP2 showed no significant propensity to adopt α-helical structure (levels < 10%) but rather 
occurred in an extended conformation, which primarily included β-type structures (levels > 
45%) and random coil architecture (levels > 45%). 
 
The anticancer activity of all known HDPs involves interaction with the plasma 
membrane of these cells, leading to cell death via either membranolytic mechanisms or 
translocation of the peptide to attack intracellular targets [9]. Cell cultures of 1321N1 and 
U87MG that had been treated with Cn-AMP2 up to a concentration of 2.0 mM showed no 
evidence of staining in the presence of Trypan blue, strongly suggesting that the anticancer 
action of the peptide does not involve membranolytic mechanisms. Reinforcing this 
suggestion, microscopic examination of these cultures showed that cells treated with Cn-AMP2 
exhibited no significant differences in morphology to that of control cells; no evidence of cell-
death, as indicated by a round morphology; and no sign of cell lysis, as witnessed by membrane 
fragmentation or the presence of cellular debris (Figure 2). In combination, these data suggest 
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that Cn-AMP2 may be cytostatic, exerting its activity against the 1321N1 and U87MG cell 
lines by entering these cells and inhibiting their ability to proliferate. The anti-proliferative 
mechanism of the peptide was not further investigated but one possibility may be that Cn-
AMP2 induces apoptotic cell death pathways via DNA-binding as was proposed for Cr-ACP1, 
which is also a mono-anionic peptide that shows anti-proliferative  activity [54].  
A clear implication from these anticancer studies is that Cn-AMP2 has the ability to 
translocate cancer cell membranes and it has previously been predicted that the peptide may 
interact with membranes via the formation of amphiphilic α-helical structure [36]. Many HDPs 
adopt this structure to facilitate partitioning into target membranes, which is reflected by their 
generally high values of <µH >, a well-established measure of amphiphilicity  [39, 40]. 
However, sequence analysis of Cn-AMP2 predicted that the peptide had only a very low 
potential to adopt α-helical structure with a mean hydrophobic moment of <µH > == 0.044, 
which was were confirmed by CD structural analysis of the peptide. This analysis showed that 
Cn-AMP2 exhibited no significant propensity to adopt this form of secondary structure under 
any of the experimental conditions investigated (Table 2; Figure 3), particularly in the presence 
of SUVs formed from DMPC / DMPS (10:1), which are generally taken to mimic cancer cell 
membranes [55]. Rather, in the presence of these SUVs and all other cases examined, the 
secondary structure of Cn-AMP2 was primarily formed from β-type structures (levels > 45%) 
and random coil architecture (> 45%) (Table 2; Figure 3), suggesting that an extended 
conformation was the membrane interactive form of the peptide. Visual examination of the 
primary structure of Cn-AMP2 [36] shows that in an extended form, the C-terminal eight 
residues of the peptide, YFVFSVGM, form a strongly hydrophobic region, which is flanked 
by a short anionic segment, TES. This residue arrangement endows Cn-AMP2 with primary 
amphiphilicity, which has been reported for other anticancer peptides such as indolicidin [56] 
and is known to mediate the ability of these peptides to traverse membranes [9, 57]. 
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Figure 4. A simulation of Cn-AMP2 interacting with a model cancer cell membrane. 
 
Figure 4 shows molecular dynamic simulations for the interaction of Cn-AMP2 with a DMPC 
/ DMPS (10:1) bilayer, which is a lipid composition generally taken to model cancer cell 
membranes [55]. In an extended conformation, Cn-AMP2 approaches the membrane surface 
(Figure 4A) and inserts (Figure 4B). Insertion of the peptide involves association of its anionic 
N-terminal segment (TES) with positively charged moieties in the head-group region of the 
bilayer such as the choline group of DMPC. Complementing these electrostatic interactions, 
the hydrophobic C-terminal segment of Cn-AMP2 (YFVFSVGM) penetrates the apolar core 
region of the membrane (Figure 4B). Led by its N-terminal region, the peptide then traverses 
this core region (Figure 4C) and emerges through the opposing leaflet to migrate away from 
the membrane surface (Figure 4D) with no significant overall perturbation of the bilayer 
resulting from the passage of Cn-AMP2 (Figures A to D). Based on the action of the peptide 
against the human glioma cell lines, 1321N1 and U87MG, it is likely that emergent Cn-AMP2 
attacks intracellular targets with the result that the ability of these cells to proliferate is inhibited 
(Figure 4E).  
  
16 
 
The ability of Cn-AMP2 was to lyse human erythrocytes and dye-filled vesicles with 
lipid compositions mimetic of cancer cell membranes was investigated and no evidence of 
either haemoglobin or calcein release was detected, indicating that the peptide had no 
detectable membranolytic ability. These results are consistent with the action of the peptide on 
1321N1 and U87MG cell lines and strongly support the suggestion that Cn-AMP2 may 
translocate cancer cell membranes to attack intracellular targets. To investigate potential 
mechanisms by which the peptide may translocate these membranes, molecular dynamic 
simulations were undertaken (Figure 4). These simulations predicted that translocation of a 
DMPC / DMPS (10:1) bilayer by Cn-AMP2 would involve a mechanism, which was based on 
the primary amphiphilicity of the peptide. As can be seen from figure 4, in an extended 
conformation, Cn-AMP2 approaches the membrane surface (Figure 4A) and inserts (Figure 
4B). Insertion of the peptide involves association of its anionic N-terminal segment (TES) with 
positively charged moieties in the head-group region of the bilayer such as the choline group 
of DMPC. Complementing these electrostatic interactions, the hydrophobic C-terminal 
segment of Cn-AMP2 (YFVFSVGM) penetrates the apolar core region of the membrane 
(Figure 4B). Led by its N-terminal region, the peptide then traverses this core region (Figure 
4C) and emerges through the opposing leaflet to migrate away from the membrane surface 
(Figure 4D) with no significant overall perturbation of the bilayer resulting from the passage 
of Cn-AMP2 (Figures A to D). Based on the action of the peptide against the human glioma 
cell lines, 1321N1 and U87MG, it is likely that emergent Cn-AMP2 then attacks intracellular 
targets such as DNA with the result that the ability of these cells to proliferate is inhibited 
(Figure 4E). 
In summary, this study has shown that Cn-AMP2 has activity against several human 
glioma, expanding the small repertoire of AHDPs known to possess anticancer activity [33, 
34]. The action of Cn-AMP2 against these cancer cells appears to involve anti-proliferative 
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mechanisms, which result from the ability of the peptide to translocate cancer cell membranes 
through a hydrophobicity-driven mechanism. Use of this mechanism would seem to reflect the 
fact that Cn-AMP2 is devoid of cationic residues and therefore lacks the capacity to engage in 
the electrostatically-driven mechanisms of cancer cell targeting utilised by most HDPs [9]. 
However, this lack of cationic residues could also give Cn-AMP2 an advantage over CHDPs 
with anticancer action whose possession of lysine and arginine residues makes them highly 
susceptible to degradation by human proteases [20, 58]. Clearly, the levels of Cn-AMP2 shown 
here to be necessary for anticancer activity are prohibitive for the therapeutic application of the 
peptide. However, given the problems due to the increasing prevalence of cancer on a global 
scale and the urgent need for solutions, we suggest that Cn-AMP2 may represent a template 
for the development of novel HDPs with clinically useful, anticancer activity. 
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